• In August 2026, TScan Therapeutics disclosed that Amgen elected to terminate their May 2023 Research Collaboration and License Agreement focused on Crohn's disease, effective November 10, 2026, with no early termination penalty and the wind-down of current research activities.
• The move ends Amgen's exclusive rights to develop and commercialize any Crohn's disease product candidates from TScan's T-cell target discovery platform, removing potential success-based milestones of over US$500.00 million and future royalties from this partnership unless Amgen or partners continue advancing related assets.
• We’ll now examine how Amgen’s exit from the Crohn’s disease collaboration with TScan reshapes its broader investment narrative and R&D priorities.

This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

Amgen Investment Narrative Recap

To own Amgen, you generally need to believe in its ability to convert a broad biologics and autoimmune pipeline into durable cash generation while managing pricing pressure, biosimilar competition, and heavy R&D spend. Amgen’s decision to exit the Crohn’s disease collaboration with TScan looks immaterial to its near term story, which is still dominated by pricing risk in core franchises and execution on late stage programs rather than this single, early stage partnership.

Against that backdrop, Amgen’s recent Q2 2026 results and raised full year guidance are more relevant to the TScan news than the termination itself. Management now expects 2026 revenue of US$38.2–39.4 billion and GAAP EPS of US$15.80–17.08, underlining how current performance and capital allocation decisions matter far more to the near term catalyst than one discontinued discovery deal in Crohn’s disease.

Yet compared with this steady picture, investors should be aware that pricing pressure on key biologics could still...

Amgen's narrative projects $41.5 billion revenue and $10.3 billion earnings by 2029.

Uncover how Amgen's forecasts yield a $371.93 fair value, a 16% downside to its current price.

Exploring Other Perspectives

Before this TScan setback, the most optimistic analysts were assuming Amgen could reach about US$44.4 billion in revenue and US$13.2 billion in earnings by 2029, which is a much more optimistic story than the consensus view and one that may now be reassessed as you weigh how much a single terminated collaboration really changes the balance between pipeline risk and future upside.

Explore 5 other fair value estimates on Amgen - why the stock might be worth as much as 56% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amgen research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.